Search
Displaying 381–390 of 998 results
-
VISIONS 2022, the national conference of the Foundation Fighting Blindness, is a one-of-a-kind event in which individuals who are visually impaired, and their families, have the opportunity to hear about exciting advancements in blindness research.
-
Ambitious Entrepreneur Won’t Let Stargardt Stop Her
Beacon StoriesBeverley is a go-getter who does not let her Stargardt disease get in the way of living her life to the fullest. When Beverley isn’t hard at work as an entrepreneur, she enjoys spending time with friends, her dog, Loki, and is also an active leader of the Foundation’s Boston Chapter.
-
Research News
The company is currently developing programs for Stargardt disease (ABCA4), Usher syndrome, RP25 (EYS), and RP1.
-
RD Fund Announces Series B Financing Behind SalioGen Therapeutics
In the PressInvestment in new portfolio company furthering genetic medicine approaches for individuals affected by retinal degenerative diseases.
-
In the Press
Series B new investors included Fidelity Management & Research Company LLC, funds and accounts advised by T. Rowe Price Associates, Inc., D1 Capital Partners, SymBiosis, the Cystic Fibrosis Foundation, and the RD Fund (the venture arm of Foundation Fighting Blindness).
-
In the Press
Dr. Thomas Chalberg has been recognized by the Foundation Fighting Blindness for his pioneering contributions to research and development.
-
In Memoriam: Dr. Alan Laties – Early Leader in Retinal Research
Beacon StoriesAlan M. Laties, MD, passed away on Sunday, December 26 at the age of 90.
-
Organizations collaborate on inherited macular dystrophy program
In the PressThe Foundation Fighting Blindness and the Nixon Visions Foundation are working together to launch the Nixon Visions Foundation Inherited Macular Dystrophy Program, according to a news release from the organizations.
-
ProQR Doses First Patients in Phase 2/3 Clinical Trials for its USH2A-Exon 13 RNA Therapy
Research NewsThe Sirius trial is for USH2A (exon 13 mutations) patients with advanced vision loss. The Celeste trial is for USH2A (exon 13 mutations) patients with moderate to early vision loss.
-
Foundation News
Program to have special translational research emphasis on inherited macular dystrophy.
